Metastatic uveal melanoma: A morphologic and immunohistochemical analysis

Cancer

Volumn 78, Issue 9, 1996, Pages 1967-1971

  Luyten, Gregorius P M ^a   Mooy, Cornelia M ^a   Post, Jannie ^a   Jensen, O A ^b   Luider, Theo M ^a   De Jong, Paul T V M ^c  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

cell type; HMB 45; metastasis; NKI C3; S 100; uveal carcinoma

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN S 100; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; UVEA MELANOMA;

ANTIGENS, NEOPLASM; HUMANS; MELANOMA; NEOPLASM PROTEINS; S100 PROTEINS; UVEAL NEOPLASMS;

EID: 0029842432     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961101)78:9<1967::AID-CNCR18>3.0.CO;2-W     Document Type: Article

References (30)

1. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993;71:2299-305.
2. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh) 1982;60:161-82.
3. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Höffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72:2219-23.
4. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1883;52:334-6.
5. Rummelt V, Folberg R, Woolson RF, Hwang T, Pe'er J. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas Ophthalmology 1995;102:844-51.
6. Luyten GPM, Mooy CM, Eijkenboom WMH, Stijnen T, Hellemons LP, Luider TM, et al. No demonstrated effect of pre-enucleation irradiation on survival of patients with uveal melanoma. Am J Ophthalmol 1995; 119:786-91.
7. Coleman K, Baak JPA, Van Diest P, Mullaney J, Farrell M, Fenton M. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 1993;77:688-92.
8. Seddon JM, Albert DM, Lavin PhT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101:1894-9.
9. Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology 1995;102:1351-61.
10. Zakka KA, Foos RY, Omphroy CA, Straatsma BR. Malignant melanoma: analysis of an autopsy population. Ophthalmology 1980;87:549-56.
11. Fuchs U, Kivelä T, Summanen P, Immonen I, Tarkkanen A. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 1992; 141:169-81.
12. Fernando SS, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI-C3 monoclonal antibody. Pathology 1994;26:16-9.
13. Burnier MN, McLean IW, Gamel JW. Immunohistochemical evaluation of uveal melanocytic tumors. Expression of HMB-45, S-100 protein, and neuron-specific enolase. Cancer 1991;68:809-14.
14. Beckenkamp G, Schafer H, von Domarus D. Immunocytochemical parameters in ocular malignant melanoma. Eur J Cancer Clin Oncol 1988;24:S41-5.
15. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 1993; 100:208-15.
16. Ringens PJ, van Haperen R, Vennegoor C, de Jong PTVM, van Duinen SG, Ruiter DJ, et al. Monoclonal antibodies in detection of choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 1989;227:287-90.
17. Kan-Mitchell J, Rao N, Albert DM, van Eldik LJ, Taylor CR. S-100 immunophenotypes of uveal melanomas. Invest Ophthalmol Vis Sci 1990;31:1492-6.
18. Cochran AJ, Lu HF, Li PX, Saxton R, Wen DR. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 1993;3:325-30.
19. Vennegoor C, Hageman Ph, van Nouhuijs H, Ruiter DJ, Calafat J, Ringens PJ, et al. A monoclonal antibody specific for cells of the melanocytic lineage. Am J Pathol 1988;130:179-92.
20. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
21. Yates AJ, Banerjee SS, Bishop PW, Graham KE. HMB-45 in non-melanocytic tumours. Histopathology 1993;23:477-8.
22. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
23. Rummelt V, Folberg R, Rummelt C, Gruman LM, Hwang T, Woolson RF, et al. Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. Ophthalmology 1994;101:718-27.
24. Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 1993;77:616-23.
25. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM. The value of nucleolar organizer regions in uveal melanoma. Am J Ophthalmol 1990;110:527-34.
26. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
27. Liotta IA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
28. Steeg PS. Genetic control of the metastatic phenotype. Semin Cancer Biol 1991;2:105-10.
29. Talmadge JE, Wolman SR, Fidler IJ. Evidence from the clonal origin of spontaneous metastasis. Science 1982;217:361-3.
30. Mooy CM, Luyten GPM, Jensen OA, Luider TM, van der Ham F, de Jong PTVM, et al. Neural cell adhesion molecule distribution in primary and metastatic uveal melanoma. Hum Pathol 1995;26:1185-90.